04.11.2025
... neuartige Version des von Genentech/Roche vermarkteten ADC Kadcyla® (ado-trastuzumab ...
01.11.2025
... %, Bayer -2,97%, Lanxess -4,53%, Roche GS -4,54%, Novartis -4,62%, Ibu ... 34% , BASF 0,94% , MorphoSys 0,15% , Roche GS -0,38% , Novartis -0,85% , Lanxess ...
01.11.2025
... Motor -2,63%, Zumtobel -4,24%, Roche GS -4,54%, Novartis -4,62%, Ford ... 86% , voestalpine 1,65% , Microsoft -0,03% , Roche GS -0,38% , Honda Motor -0,71 ...
27.10.2025
... (94) EUR - 'BUY' - JEFFERIES SENKT ROCHE AUF 'UNDERPERFORM' (HOLD) - ZIEL 230 ...
25.10.2025
... Amgen -0,99%, Stratec Biomedical -3,66%, Roche GS -4,41%, Valneva -6,49%, ... , Pfizer 2,61% , Amgen 2,41% , Roche GS 2,26% , BASF 2,03% , Linde ...
25.10.2025
... -1,14%, Johnson & Johnson -1,46%, Roche GS -4,41% und GlaxoSmithKline -19 ... Corp. 2,99% , Pfizer 2,61% , Roche GS 2,26% , Microsoft 1,19% , Alphabet ...